The Uromigos

Episodes

Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria

February 16, 2026

PCWG 4 updates prostate cancer trial criteria with new patient-centric nomenclature, revised PSMA PET imaging rules, and biomarker integration.

Episode 476: ASCO GU 2026 Preview

February 9, 2026

Experts preview ASCO GU 2026, highlighting pivotal Phase III trials for kidney (Belzutafan), bladder (EV-Pembro), and prostate cancer.

Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis

February 2, 2026

FDA analysis of mRCC trials shows deeper tumor shrinkage continuously predicts better survival, with no clear threshold and differences by regimen.

Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer

January 26, 2026

Experts discuss IO & ADC re-challenge in urothelial cancer, a data-free zone where patient selection and prior response are key considerations.

Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer

January 19, 2026

The EMBARK trial's impressive MFS/OS data in BCR prostate cancer face new challenges from PSMA PET imaging and questions on trial design.

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer

January 12, 2026

Experts discuss managing variant histology bladder cancer, highlighting when to alter therapy for pure variants vs. using EV+Pembro for mixed types.

Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer

January 5, 2026

Experts discuss the next wave of prostate cancer therapies: bispecific T-cell engagers (BiTEs) and ADCs, detailing ongoing Phase 3 trials.

Episode 470: Bladder Cancer Year in Review

December 29, 2025

2025 was a 10/10 year for bladder cancer. EV-Pembro transforms MIBC, new ADCs emerge, and ctDNA refines adjuvant care. A deep dive review.

Episode 469: Prostate Cancer year in Review

December 22, 2025

Prostate cancer experts review 2025's key trials, highlighting the rise of personalized therapy, the need for better patient selection, and chemotherapy's enduring value.

Episode 468: RCC Year in Review

December 15, 2025

Uromigos podcast recaps 2025 kidney cancer data: the Rampart study reinforces adjuvant IO, Kim1 shows biomarker promise, and combos advance.

Episode 467: The Uromigos Score for MIBC and Advanced Urothelial Cancer

December 9, 2025

Experts use the Uromigos score to rank bladder cancer treatments, revealing a consensus shift towards ADC-based combos as the new standard of care.

Episode 442: The History of ARPI Development in Prostate Cancer

November 24, 2025

Experts discuss the transformative journey of ARPIs in prostate cancer, from pivotal trials to future de-intensification strategies.

Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC

November 10, 2025

Experts debate adjuvant kidney cancer therapy, dissecting KEYNOTE-564's survival benefit, RAMPART's promise, and LITESPARK-022's surprising data.

Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC

November 10, 2025

Experts debate adding a third agent to the mHSPC backbone, weighing docetaxel, PARP inhibitors, and lutetium based on new trial data.

Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer

November 8, 2025

Experts debate the PSMA-addition trial for radioligand therapy in prostate cancer, weighing early RPFS gains against toxicity and trial design.

Episode 458: #UromigosLive 2025 - Mock ODAC

November 8, 2025

Mock ODAC debates immunotherapy for bladder cancer. Do modest efficacy gains from cisanlimab & durvalumab justify significant toxicity risks?

Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer

November 7, 2025

Experts debate DV-Toripalumab's impact on urothelial cancer, comparing it to EV-Pembro and questioning HER2 biomarkers and future ADC sequencing.

Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer

November 7, 2025

Experts debate the transformative EV Pembro trial for bladder cancer, signaling a shift to neoadjuvant therapy and questioning surgery's future role.